CTKB — Cytek Biosciences, Inc.

Summary of Cytek Biosciences Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $62.1 million, an 8% increase year-over-year, marking the highest quarterly revenue in the company's history.
• Full Year 2025 Revenue: $201.5 million, a 1% increase compared to 2024.
• Gross Profit: Q4 gross profit was $32.9 million (53% margin), down from $33.7 million (59% margin) in Q4 2024. Full-year gross profit was $104.5 million (52% margin), down from 55% in 2024.
• Net Loss: Q4 net loss of $44.1 million, significantly impacted by a $38.1 million valuation allowance on deferred tax assets. Excluding this, the adjusted net loss would have been $6.0 million. Full-year net loss was $66.5 million.
• Adjusted EBITDA: Q4 adjusted EBITDA declined to $4.5 million from $12.5 million in the prior year. Full-year adjusted EBITDA was $5 million, down from $22.4 million in 2024.

2. Strategic Updates and Business Highlights

• Revenue Growth Drivers: Growth was attributed to strong performance in service and reagents, particularly in the APAC and EMEA regions. The U.S. saw mid-single-digit growth driven by academic and government markets.
• Instruments and Products: Cytek expanded its installed base by 208 instruments, totaling 3,664 units. The new Aurora Evo system contributed significantly to growth, with a 21% increase in unit sales.
• Recurring Revenue: Recurring revenue represented 34% of total revenue, growing 21% year-over-year.
• Operational Improvements: A new manufacturing facility in Singapore began generating revenue within 100 days, enhancing supply chain resilience.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Projected revenue between $205 million and $212 million, assuming constant currency rates. This reflects improved market conditions in EMEA and the U.S., alongside continued growth in APAC.
• Market Expectations: The company anticipates ongoing growth in service and reagent revenues, with modest growth in instruments.

4. Bad News, Challenges, or Points of Concern

• Declining Metrics: Gross profit margins declined due to higher material costs, tariffs, and increased operational expenses. Operating expenses rose significantly, leading to a loss from operations of $40.4 million for the year.
• Market Volatility: The company experienced fluctuations in demand, particularly from the biotech and pharma sectors, which impacted revenue stability.
• Deferred Tax Asset Valuation: The substantial write-off against deferred tax assets raises concerns about future tax benefits and reflects underlying uncertainties in financial performance.

5. Notable Q&A Insights

• Market Growth Assumptions: Management discussed the flow cytometry market's growth, noting APAC's strong performance and challenges in EMEA and the U.S. They expect a rebound in market growth rates.
• Budget Cycles: The fourth quarter's growth was attributed to normalization in academic and government spending, with some catch-up disbursements from the NIH.
• Customer Acquisition vs. Expansion: The company noted a mix of new customer acquisitions and existing customers expanding their capacity, with a focus on high-end market segments.
• Commercial Investments: Cytek plans to continue investing in sales teams and reagent sales to drive future revenue growth, while maintaining competitive pricing strategies.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, challenges faced, and insights from the Q&A, providing a comprehensive overview of Cytek Biosciences' performance and outlook.